Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could ease bulging eyes in thyroid disease

NCT ID NCT06625398

Disease control Sponsor: Viridian Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This phase 3 trial tests an investigational drug called VRDN-003 in 204 people with chronic thyroid eye disease (TED). The drug is given as a shot under the skin and aims to reduce eye bulging and other symptoms. Participants are randomly assigned to receive either VRDN-003 or a placebo, and neither they nor their doctors know which they receive. The study is active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VRDN-003 (a drug that blocks a specific receptor to reduce inflammation and tissue swelling)
What this could lead to
If it works, this could provide a new treatment option for people with chronic thyroid eye disease, reducing eye bulging and discomfort without the need for surgery.
What could go wrong
This is a phase 3 trial, but results are not yet known. The drug may not work better than placebo, and side effects are possible. It is also only for people with chronic TED, not for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

204 people

The number who actually took part.

Started

Aug 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Must have moderate to severe chronic TED, with any CAS (0-7) on the 7-item scale, and with documented evidence of ocular symptoms or signs that began greater than 15 months prior to screening * Must agree to use highly effective contraception as specified in the protocol * Female TED participants must have a negative serum pregnancy test at screening Key Exclusion Criteria: * Must not have received prior treatment with another anti-IGF-1R therapy * Must not have received systemic corticosteroids or steroid eye drops for any condition, including TED, or selenium within 2 weeks prior to first dose. * Must not have received other immunosuppressive drugs for any condition, including TED, or any other therapy for TED within 12 weeks prior to first dose * Must not have received an investigational agent for any condition, including TED, within 8 weeks or longer duration (depending on the type of investigational agent) prior to first dose * Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose * Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit * Must not have a pre-existing ophthalmic condition in the study eye which in the study doctor's opinion, would interfere with interpretation of study results * Must not have abnormal hearing test before first dose. Must also not have a history of ear conditions considered significant by study doctor * Must not have a history of inflammatory bowel disease * Female TED participants must not be pregnant or breastfeeding NOTE: There are additional eligibility criteria for participants who do not have a meaningful response at Week 24 (irrespective of initial treatment arm) who may receive additional injections of VRDN-003. These are described in the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thyroid eye disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid eye disease

Contacts and locations

Locations

  • A.P.J. Office

    Newport Beach, California, 92660, United States

  • Advancing Research International, LLC

    Los Angeles, California, 90023, United States

  • Agile Clinical Research Trials, LLC

    Atlanta, Georgia, 30328, United States

  • Alliance Research Institute - Canoga Park

    Canoga Park, California, 91304, United States

  • Alliance Research Institute - Lynwood

    Lynwood, California, 90262, United States

  • Amsterdam UMC

    Amsterdam, 1081 HZ, Netherlands

  • Anmed Health Services LLC

    Miami, Florida, 33193, United States

  • Asheville Clinical Research

    Asheville, North Carolina, 28803, United States

  • Baylor College of Medicine/Alkek Eye Center

    Houston, Texas, 77030, United States

  • Byers Eye Institute at Stanford University

    Palo Alto, California, 94303, United States

  • Centrum Medyczne Pratia Gdynia

    Gdynia, 81-338, Poland

  • Centrum Medyczne Pulawska Sp. z o.o.

    Piaseczno, 05 500, Poland

  • Charité Universitätsmedizin Berlin KöR

    Berlin, 13353, Germany

  • Cockerham Eye Consultants, PC

    San Diego, California, 92108, United States

  • Complexo Hospitalario Universitario De Santiago

    Santiago de Compostela, A Coruña, 15706, Spain

  • Duke Eye Center

    Durham, North Carolina, 27710, United States

  • ETG Lublin

    Lublin, 20-412, Poland

  • Erasmus Medical Center

    Rotterdam, 3015, Netherlands

  • Eskulap Pabianice Sp. z o.o.

    Pabianice, 95-200, Poland

  • Fraser Eye Care Center

    Fraser, Michigan, 48026, United States

  • Ganglion Orvosi Kozpont - Nozologen Kft - Szemeszet

    Budapest, 1133, Hungary

  • Ganglion Orvosi Kozpont - Nozologen Kft - Szemeszet

    Pécs, H-7621, Hungary

  • Gulf Coast Clinical Trials

    Houston, Texas, 77070, United States

  • Horizon Clinical Research Group

    Cypress, Texas, 77429, United States

  • Hospital Arruzafa / Metavisión Arruzafa, S.L

    Córdoba, 14012, Spain

  • Hospital Clínico San Carlos de Madrid

    Madrid, 28043, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario Virgen Macarena

    Seville, 41009, Spain

  • Hype Clinical Research LLC

    Miami, Florida, 33145, United States

  • Ilumina Medical Research

    Kissimmee, Florida, 34744, United States

  • Kahana Oculoplastic & Orbital Surgery

    Livonia, Michigan, 48152, United States

  • Klinikapotheke des Universitätsklinikums Gießen und Marburg GmbH (UKGM)

    Giessen, 35392, Germany

  • Marvel Clinical Research

    Huntington Beach, California, 92647, United States

  • Massachusetts Eye and Ear

    Boston, Massachusetts, 02114, United States

  • Med-Care Research

    Miami, Florida, 33125, United States

  • Neuro-Eye Clinical Trials

    Houston, Texas, 77074, United States

  • Opthalmic Consultants of Boston

    East Weymouth, Massachusetts, 02189, United States

  • Pasadena Clinical Trials

    Pasadena, California, 91101, United States

  • Pecsi Tudomanyegyetem Klinikai Kozpont, Szemeszeti Klinika

    Pécs, 7623, Hungary

  • Polimedica PTG

    Warsaw, 02-793, Poland

  • Roski Eye Institute, Keck School of Medicine, USC

    Los Angeles, California, 90033, United States

  • Rutgers New Jersey Medical School

    Newark, New Jersey, 07103, United States

  • S.L. Office

    Las Vegas, Nevada, 89144, United States

  • Santa Familia PTG Lodz

    Lodz, 90-302, Poland

  • Sarasota Retina Institute

    Sarasota, Florida, 34239, United States

  • Scheie Eye Institute Penn Presbyterian

    Philadelphia, Pennsylvania, 19104, United States

  • Scottsdale Clinical Trials

    Scottsdale, Arizona, 85260, United States

  • Southern Clinical Research LLc

    Miami, Florida, 33990, United States

  • United Medical Research Institute

    Inglewood, California, 90301, United States

  • University Health

    Kansas City, Missouri, 64108, United States

  • University of Washington, Eye institute

    Seattle, Washington, 98104, United States

  • Universitätsklinikum Carl- Gustav- Carus- Dresden

    Dresden, 1307, Germany

  • Universitätsmedizin Göttingen

    Göttingen, 37075, Germany

  • Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz, Szemeszeti Osztaly

    Szombathely, 9700, Hungary

  • Vector Clinical Trials

    Sparks, Nevada, 89436, United States

  • Vision Medical Research

    Orland Park, Illinois, 60462, United States

  • Warszawski Szpital Okulistyczny

    Warsaw, 01-258, Poland

  • West Virginia University Eye Institute

    Morgantown, West Virginia, 26506, United States

  • Wills Eye Hospital

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.